This study evaluates the supervivence of cirrhotic patients that develop portal vein thrombosis in comparison to cirrhotic patients that do not develop portal vein thrombosis.
Patients newly diagnosed with portal vein thrombosis by imaging tests, that evaluate the extent and exclude tumoral origin, will be included (informed consent previously signed). Anticoagulant treatment will be initiated according to clinical guidelines (if there is no contraindication) first with LMWH (low molecular weight heparin) and later with dicoumarin. An abdominal CT will be performed to evaluate the extent and exclude tumoral origin; a gastroscopy to evaluate portal hypertension (and do prophylaxis if required) and thrombophilia study. Patients will be followed by imaging and laboratory tests every 6 months; to evaluate the response to the treatment and detect any cirrhosis complication.
Study Type
OBSERVATIONAL
There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
Survival of patients with cirrhosis
Time frame: 12 months
Complications related with cirrhosis
Number of patients with Complications related with cirrhosis including ascites, hepatic encephalopaty, and variceal bleeding
Time frame: 12 months
Complications related with anticoagulation treatment
Number of patients with Complications related with anticoagulation treatment including any haemorragic event
Time frame: 12 months
Prevalence of thrombophilic disorders in patients with Portal Vein Thrombosis
To know how many patients with Portal Vein Thrombosis have Thrombophilic disorders
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.